| Autor: |
T J, Gao, G Y, Han, F M, Lu |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 27(11) |
| ISSN: |
1007-3418 |
| Popis: |
Hepatocellular carcinoma (HCC) is a common malignant tumor in China, and most of the patients have a background of chronic HBV infection. Nucleos(t)ide drugs (NAs) are currently recommended by major guidelines as a first-line treatments for chronic hepatitis B. However, it is still clinically possible to observe that some patients who have acquired virological response (HBV DNA below the lower detection limit) after NAS treatment progress to HCC, and its mechanism of development is still unclear. In this review, the mechanism relevant to HCC progression in treatment of chronic hepatitis B patients with NAs is analyzed mainly from the aspects of gene integration and persistent inflammatory injury.肝细胞癌（HCC）是我国常见的恶性肿瘤，其中大部分患者有慢性乙型肝炎病毒（HBV）感染背景。核苷（酸）类药物（NAs）是目前各大指南推荐的治疗慢性乙型肝炎的一线用药。然而，在临床上观察到部分接受NAs治疗且已经获得病毒学应答（HBV DNA低于检测下限）的患者仍可以进展为HCC，其发展机制尚不明确。现主要从病毒基因整合和持续的肝脏炎症损伤方面对NAs治疗下慢性乙型肝炎患者进展为HCC的相关机制进行分析。. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
